The global branded generics market size valued US$ 224.0 billion in 2017 and expected to reach US$ 350.0 billion by 2023, poised to grow at CAGR 7.7 % during forecast period 2021-2023. Branded generics are the most recent version of an off-patent drug that is promoted by either a patented drug manufacturer or generic drug companies that build brand equity for their generic drug versions. The pharmaceutical sector is characterised by a number of internal and external dynamics linked to licencing, production, and marketing. The notion of patenting is extremely important in the pharmaceutical industry. The branded generics market expected to register around double-digit growth rate in emerging economies owing to the widespread prevalence of lifestyle and chronic diseases like diabetes and cardiovascular diseases. The growing lifestyle changes along with rising disposable income in middle classes are factors expected to prompt the market growth in near future. According to International Diabetes Federation (IDF) atlas, 2015 emerging nations like India and China, Brazil and Russia fall under top ten countries for diabetic population. This report studies branded generics market dynamics in emerging markets and developed markets elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes new product introductions, recent drug patent expiration data, regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the competition. Moreover, PBI analyzed branded generics market to better equip clients with possible investment opportunities across the emerging markets (Regional Investment Hot-Spots) and unmet needs (Product/Disease Opportunities).